Skip to main content
OpenTrials
Completed

NCT Number: NCT06653361

Ultra-Widefield Fluorescein Angiography-Based Targeted Retinal Photocoagulation Versus Conventional Panretinal Photocoagulation in the Preservation of Visual Function and Regression of Proliferative Diabetic Retinopathy

Proliferative diabetic retinopathy is a vision-threatening disease that can lead to irreversible visual loss. The treatment options for proliferative diabetic retinopathy are anti-VEGF injection and retinal photocoagulation. The study aims to compare ultra-widefield fluorescein angiography-based targeted retinal photocoagulation and panretinal photocoagulation in the treatment of proliferative diabetic retinopathy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Proliferative Diabetic Retinopathy - High Risk Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Diabetic Angiopathies Diabetic Retinopathy Endocrine System Diseases Eye Diseases Retinal Diseases Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Khyber Teaching Hospital Peshawar

Peshawar, Khyber Pakhtunkhwa, 25000, Pakistan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • proliferative diabetic retinopathy (PDR) with neovascularization on the disc or elsewhere in the retina

Exclusion criteria

  • Participants with a history of previous history of:
  • retinal photocoagulation
  • vitreoretinal surgery
  • tractional retinal detachment
  • epiretinal membrane
  • vitreomacular traction
  • glaucoma
  • uveitis
  • media opacities like cataract, corneal opacity, vitreous hemorrhage
  • anti-VEGF injections in last 3 months

Treatment and study plan

Green laser

Procedure

Green Laser

Primary outcomes

  1. BCVA

    Time frame: 2 months

    Best Corrected Visual Acuity

  2. CMT

    Time frame: 2 months

    Central Macular Thickness

  3. MD

    Time frame: 2 months

    Mean Deviation

  4. VFI

    Time frame: 2 months

    Visual Filed Index

Sponsors and collaborators

Lead sponsor

Hayatabad Medical Complex

Other Gov

Collaborators

  • Khyber Teaching Hospital

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Oct 22, 2024
Registry last updated
Oct 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.